Format
Sort by
Items per page

Send to

Choose Destination

Best matches for FILGRASTIM/AE:

Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. Pettengell R et al. Support Care Cancer. (2016)

[Duration of filgrastim prophylaxis for chemotherapy-induced neutropenia and its predictors]. Yang S et al. Zhonghua Zhong Liu Za Zhi. (2016)

G-CSF: filgrastim, lenograstim and biosimilars. Welte K et al. Expert Opin Biol Ther. (2014)

Search results

Items: 1 to 20 of 52

1.

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.

Choi C, Yoo BW, Kim CO, Hong T, Jin BH, Seo KS, Jang JY, Park MS.

Drug Des Devel Ther. 2018 Aug 1;12:2381-2387. doi: 10.2147/DDDT.S158277. eCollection 2018.

2.

Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor.

Iwamoto H, Izumi K, Natsagdorj A, Makino T, Nohara T, Shigehara K, Kadono Y, Mizokami A.

In Vivo. 2018 Jul-Aug;32(4):899-903. doi: 10.21873/invivo.11326.

3.

A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.

Waller CF, Tiessen RG, Lawrence TE, Shaw A, Liu MS, Sharma R, Baczkowski M, Kothekar MA, Micales CE, Barve A, Ranganna GM, Pennella EJ.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1087-1095. doi: 10.1007/s00432-018-2643-3. Epub 2018 Apr 18.

PMID:
29671069
4.

Pseudogout Attack after Pegfilgrastim Administration in Anaplastic Large Cell Lymphoma.

Hatayama M, Ikuta K, Ishioh M, Saito T, Toki Y, Yamamoto M, Shindo M, Torimoto Y, Okumura T.

Intern Med. 2018 Jun 15;57(12):1779-1782. doi: 10.2169/internalmedicine.9362-17. Epub 2018 Feb 9.

5.

Clinical safety and efficacy of "filgrastim biosimilar 2" in Japanese patients in a post-marketing surveillance study.

Tamura K, Hashimoto K, Nishikawa K.

J Infect Chemother. 2018 May;24(5):363-369. doi: 10.1016/j.jiac.2017.12.011. Epub 2018 Feb 3.

6.

The Case | Acute kidney injury in a 78-year-old man with low-grade B-cell lymphoma.

Elabd H, Nayak R, Rashid T, Stokes MB.

Kidney Int. 2018 Jan;93(1):275-276. doi: 10.1016/j.kint.2017.07.001. No abstract available.

PMID:
29291825
7.
8.

[Diffuse large B-cell lymphoma complicated with drug-induced vasculitis during administration of pegfilgrastim].

Ito Y, Noda K, Aiba K, Yano S, Fujii T.

Rinsho Ketsueki. 2017;58(11):2238-2242. doi: 10.11406/rinketsu.58.2238. Review. Japanese.

PMID:
29212975
9.

A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.

Douglas AG, Schwab P, Lane D, Kennedy K, Slabaugh SL, Bowe A.

J Manag Care Spec Pharm. 2017 Dec;23(12):1221-1226. doi: 10.18553/jmcp.2017.23.12.1221.

10.

Pharmacovigilance of Biologics in a Multisource Environment.

Sagi S, Cohen HP, Woollett GR.

J Manag Care Spec Pharm. 2017 Dec;23(12):1249-1254. doi: 10.18553/jmcp.2017.23.12.1249.

11.

Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.

Li E, Lobaina E.

J Manag Care Spec Pharm. 2017 Dec;23(12):1227-1232. doi: 10.18553/jmcp.2017.23.12.1227.

12.

Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center.

Nelson CA, Noe MH, McMahon CM, Gowda A, Wu B, Ashchyan HJ, Perl AE, James WD, Micheletti RG, Rosenbach M.

J Am Acad Dermatol. 2018 Feb;78(2):303-309.e4. doi: 10.1016/j.jaad.2017.09.013. Epub 2017 Oct 26.

PMID:
29107342
13.

Premature ventricular contractions as a side effect of filgrastim in a child with B-thalassaemia.

Nazir HF, Joshi N, Wali YA.

Cardiol Young. 2018 Jan;28(1):155-158. doi: 10.1017/S1047951117001585. Epub 2017 Aug 29.

PMID:
28847319
14.

The First Case of Pseudomonas aeruginosa Bacteremic Pneumonia in a Cancer Patient Receiving Pegfilgrastim.

Morita F, Hirai Y, Suzuki K, Uehara Y, Mitsuhashi K, Takahashi M, Watanabe S, Naito T.

Intern Med. 2017;56(15):2039-2042. doi: 10.2169/internalmedicine.56.8245. Epub 2017 Aug 1.

15.

Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.

Blackwell K, Gascon P, Jones CM, Nixon A, Krendyukov A, Nakov R, Li Y, Harbeck N.

Ann Oncol. 2017 Sep 1;28(9):2272-2277. doi: 10.1093/annonc/mdx303.

16.

Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.

Kobayashi T, Kamada I, Komura J, Toyoshima S, Ishii-Watabe A.

Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):917-924. doi: 10.1002/pds.4218. Epub 2017 Jun 14.

PMID:
28612945
17.

Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.

Donkor KN, Selim JH, Waworuntu A, Lewis K.

Ann Pharmacother. 2017 Oct;51(10):840-847. doi: 10.1177/1060028017714554. Epub 2017 Jun 9.

PMID:
28597691
18.

Thoracic aortitis and aortic dissection following pegfilgrastim administration.

Sato Y, Kaji S, Ueda H, Tomii K.

Eur J Cardiothorac Surg. 2017 Nov 1;52(5):993-994. doi: 10.1093/ejcts/ezx165.

PMID:
28549110
19.

Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.

Ri M, Matsue K, Sunami K, Shimazaki C, Hayashi A, Sunaga Y, Sasaki T, Suzuki K.

Int J Hematol. 2017 Oct;106(4):562-572. doi: 10.1007/s12185-017-2255-8. Epub 2017 May 19.

PMID:
28527129
20.

Supplemental Content

Loading ...
Support Center